Source: Pediatric Blood & Cancer. Unidade: FMRP
Subjects: ANTICORPOS MONOCLONAIS (TERAPIA), CRIANÇAS, LINFOMA
ABNT
VALERA, Elvis Terci et al. Anti-CD20 monoclonal antibody therapy and minimal residual disease status of T-cell/histiocyte-rich large B cell non-hodgkin lymphoma. [Carta ao Editor]. Pediatric Blood & Cancer. Hoboken: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 31 out. 2024. , 2011APA
Valera, E. T., Queiroz, R. G. de P., Brassesco, M. S., Scrideli, C. A., Neves, F., & Tone, L. G. (2011). Anti-CD20 monoclonal antibody therapy and minimal residual disease status of T-cell/histiocyte-rich large B cell non-hodgkin lymphoma. [Carta ao Editor]. Pediatric Blood & Cancer. Hoboken: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo.NLM
Valera ET, Queiroz RG de P, Brassesco MS, Scrideli CA, Neves F, Tone LG. Anti-CD20 monoclonal antibody therapy and minimal residual disease status of T-cell/histiocyte-rich large B cell non-hodgkin lymphoma. [Carta ao Editor]. Pediatric Blood & Cancer. 2011 ;[citado 2024 out. 31 ]Vancouver
Valera ET, Queiroz RG de P, Brassesco MS, Scrideli CA, Neves F, Tone LG. Anti-CD20 monoclonal antibody therapy and minimal residual disease status of T-cell/histiocyte-rich large B cell non-hodgkin lymphoma. [Carta ao Editor]. Pediatric Blood & Cancer. 2011 ;[citado 2024 out. 31 ]